profit from every $100 of sales.
$0$100
Avantor
$15.91+2.84% today
+37.7% in 1 year
1-year low $7.411-year high $17.29
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Avantor sold, what it kept, and what it did with the cash.
Sales went from $7.51 billion in 2022 to $6.55 billion in 2025, with -$530 million of profit last year.
SalesProfit
Avantor handed back 16% of the cash it generated last year.
Buybacks $81M
Free cash flow 2025$495M
Bought back its own shares$81M
Paid as dividends–
Cash vs. debt$365M vs. $3.9B
Avantor vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Avantor | No profit yet | ||
 ResMed | 21.8× · Fair price | ||
 West Pharmaceutical Services | 58.3× · Expensive | ||
 Hologic | 30.0× · Fair price | ||
 Baxter International | No profit yet |
AI analysis
An AI analyst reads Avantor's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 6,394 | 7,386 | 7,512 | 6,967 | 6,784 | 6,552 | |
| 2,081 | 2,503 | 2,603 | 2,364 | 2,279 | 2,139 | |
| – | – | 1,130 | 857 | 638 | 544 | |
| 765 | 1,350 | 1,522 | 1,098 | 1,478 | 139 | |
| 117 | 573 | 687 | 321 | 712 | -530 | |
| 0.09 | 0.85 | 1.01 | 0.47 | 1.04 | -0.78 | |
| 32.5% | 33.9% | 34.6% | 33.9% | 33.6% | 32.7% | |
| – | – | 15.0% | 12.3% | 9.4% | 8.3% | |
| 1.8% | 7.8% | 9.1% | 4.6% | 10.5% | -8.1% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 9,907 | 13,897 | 13,464 | 12,973 | 12,115 | 11,795 |
| Cash | 287 | 302 | 373 | 263 | 262 | 365 |
| Total debt | 4,894 | 7,023 | 6,288 | 5,537 | 4,056 | 3,946 |
| Total liabilities | 7,232 | 9,700 | 8,609 | 7,720 | 6,158 | 6,230 |
| 2,674 | 4,197 | 4,855 | 5,253 | 5,957 | 5,565 | |
| 583 | 600 | 679 | 678 | 682 | 681 | |
| 3.9% | 6.8% | 7.9% | 5.1% | 8.5% | -2.3% | |
| 4.4% | 13.6% | 14.1% | 6.1% | 11.9% | -9.5% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 930 | 954 | 844 | 870 | 841 | 624 | |
| 62 | 111 | 133 | 146 | 149 | 129 | |
| 868 | 843 | 710 | 724 | 692 | 495 | |
| Dividends paid | – | – | 32 | 0 | 0 | – |
| – | – | 13 | 14 | 9 | 81 | |
| 44 | 51 | 46 | 41 | 47 | 46 |
Valuation
- –
- 20.2×
- –
- 0.9×
- 1.6×
- 21.8×
- 103.5×
- 4.6%
- -4.9%
- 0.0%
Profitability
- 32.7%
- 8.3%
- -8.1%
- 2.0%
- -2.7%
- 3.2%
- -9.6%
- -4.7%
- -2.7%
- –
Growth
- +0.5%
- –
- −28.5%
- –
- +3.5%
Financial health
- 25.8×
- 0.01
- 0.3%
- -1.5×
- 1.76
- 1.17
- 0.56
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 34%of 948
Bottom 48%of 871
Bottom 17%of 868
Top 23%of 985
What analysts expect
- Average price target
- $9.50
- Range
- $7.00 – $11.00
- 8 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 29, 2026 | 0.17 | 0.16 | +6.3% |
| Feb 11, 2026 | 0.22 | 0.21 | +4.8% |
| Oct 29, 2025 | 0.22 | 0.22 | −2.1% |
| Aug 1, 2025 | 0.24 | 0.25 | −4.0% |
| Apr 25, 2025 | 0.23 | 0.23 | −0.6% |
| Feb 7, 2025 | 0.27 | 0.25 | +8.0% |
| Oct 25, 2024 | 0.26 | 0.25 | +2.1% |
| Jul 26, 2024 | 0.25 | 0.23 | +7.6% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
17No pass
Benjamin Graham
58No pass
Philip Fisher
19No pass
Peter Lynch
29No pass
Joel Greenblatt
0No pass
Charlie Munger
18No pass
Terry Smith
10No pass
Questions about Avantor
Is Avantor a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Avantor AI analysis
What does Avantor do?
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. It is in Medical - Instruments & Supplies, based in Radnor, PA, United States, with 13,500 employees.
Does Avantor pay a dividend?
No. Avantor does not pay a dividend at the moment; in 2025 it returned $80.7 million to shareholders by buying back its own shares.
Is Avantor stock halal?
No. Avantor does not pass our halal screen: its debt is 37% of its market value, at or above the 33% limit. How we check
How has Avantor stock done over the past year?
Up 37.7% over the past twelve months, to $15.91. It traded between $7.41 and $17.29 and is 8.0% below its high.
Who are Avantor's competitors?
The largest listed companies in the same industry are ResMed, West Pharmaceutical Services, Hologic and Baxter International. The peers table on this page compares their profit, growth and price with Avantor's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.